Saniona – Company introduction

Saniona – Company introduction

Saniona - Company introduction 19 JanuarJan 2022 15:00 - 15:30Online Event

Meet CEO Rami Levin and Investor Relations Trista Morrison when they give an introduction to Saniona.
The introduction will be followed by a Q&A session.

Saniona is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for patients suffering from rare diseases for which there are a lack of available treatment options. The company’s lead product candidate, Tesomet, is in mid-stage clinical trials for hypothalamic obesity and Prader-Willi syndrome, serious rare disorders characterized by severe weight gain, disturbances of metabolic functions and uncontrollable hunger. Saniona has developed a proprietary ion channel drug discovery engine anchored by IONBASE™, a database of more than 130,000 compounds, of which more than 20,000 are Saniona’s proprietary ion channel modulators. Through its ion channel expertise, Saniona is advancing two wholly-owned ion channel modulators, SAN711 and SAN903. SAN711 is in a Phase 1 clinical trial and may be applicable in the treatment of rare neuropathic disorders, and SAN903 is in preclinical development for rare inflammatory, fibrotic and hematological disorders. Led by an experienced scientific and operational team, Saniona has an established research organization in the Copenhagen area, Denmark, and a corporate office in the Boston, Massachusetts area, U.S. The company’s shares are listed on Nasdaq Stockholm Small Cap.

The presentation will be in English

Disclaimer: HC Andersen Capital receives payment from the company for a Digital IR / Corporate Visibility subscription agreement. The content does not make recommendations to buy, sell or hold. HC Andersen Capital is an information platform that connects investors and listed companies.

Information

Saniona - Company introduction 19 JanuarJan 2022 15:00 - 15:30
Saniona - Company introduction Online Event
Saniona